RETURN ON INNOVATION

Why global health R&D is a smart investment for the United States

July 20, 2017





































































Overview: Report key findings



COURTNEY CARSON

Policy and Advocacy Officer, Global Health Technologies Coalition




@GHTCoalition



Downward trend of US government investments in global health R&D


US government funding for global health R&D, 2007-2015






US government investments in global health R&D are limited, but indispensable

US government investment, 2015





US government investments in global health R&D are limited, but indispensable






US government investments respond to market failure

- Endemic and emerging global health challenges disproportionally affect people in the world's poorest places
- US government jumpstarts research, de-risks investment
- The private sector alone will not fill this gap






Whole-of-government support for global health R&D





Impact: New technologies developed


US government support for new global health technologies registered since 2000





Impact: Promising tools in pipeline

US government support for late-stage global health pipeline candidates





US-supported tools are savings lives, lowering healthcare and treatment costs



50-cent meningitis A vaccine



Two pediatric malaria treatments supported

USAID, CDC, NIH, FDA	NIH, USAID
673,000 cases of meningitis A prevented	300 million treatments distributed
378,000 deaths averted	750,000 estimated children saved
63,000 children saved from disability	
\$9 billion dollars saved v. treating meningitis A	



US investments in global health R&D create jobs and economic growth

89¢ of every dollar invested benefits US-based research


Global health R&D injected \$12 billion into the American economy



200,000
new US jobs
\$33billion
in economic output



US investments in global health R&D leverage private sector funding





US investments in global health R&D promote cost-savings



in polio vaccine R&D in the 1950s has



in treatment costs in the United States alone

\$50 million

to develop MenAfriVac – a low-cost meningitis A vaccine

By 2020, it is predicted to have

saved \$9 billion

> in meningitis A treatment costs

Large-scale disease pandemics could cost the global economy more than


\$60 billion a year

An R&D investment of \$1 billion per year

could deliver the tools needed to protect against these outbreaks




US investments in global health R&D protect American health





US investments in global health R&D protect American health


Chagas' disease: annual cost to the US economy vs. current US government R&D investment





Returns not reflected in global health R&D prioritization or funding

US government funding for global health R&D, 2007-2015





Global health R&D is a best buy for America



GLOBAL HEALTH SECURITY

SMALL INVESTMENT, BIG IMPACT \(\(\tilde{\t 2 AMERICAN LEADERSHIP



RETURN ON INNOVATION

Why global health R&D is a smart investment for the United States

July 20, 2017



